Kymera Therapeutics (NASDAQ: KYMR) CEO reports option exercise and share sale

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. reported an insider equity transaction by its Chief Executive Officer, who is also a director. On 12/31/2025, the reporting person exercised a stock option for 30,000 shares of common stock at an exercise price of $2.08 per share and acquired those shares. On the same date, the reporting person sold a total of 30,000 shares of common stock in two transactions: 23,986 shares at a weighted average price of $77.9508 and 6,014 shares at a weighted average price of $78.5187, all pursuant to a Rule 10b5-1 trading plan adopted on September 6, 2024. Following these transactions, the reporting person beneficially owned 663,077 shares of common stock directly and 275,559 derivative securities (stock options), with the option relating to these 30,000 shares fully vested and exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mainolfi Nello

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/31/2025		M(1)		30,000	A	$2.08	693,077	D
Common Stock	12/31/2025		S(1)		23,986	D	$77.9508(2)	669,091	D
Common Stock	12/31/2025		S(1)		6,014	D	$78.5187(3)	663,077	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.08	12/31/2025		M(1)			30,000	(4)	11/13/2029	Common Stock	30,000	$0	275,559	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024 adopted by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.44 to $78.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.44 to $78.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	12/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kymera Therapeutics (KYMR) report for its CEO on 12/31/2025?

The CEO of Kymera Therapeutics, Inc. (KYMR), who is also a director, reported exercising a stock option for 30,000 shares of common stock at an exercise price of $2.08 per share and acquiring those shares on 12/31/2025.

How many Kymera Therapeutics (KYMR) shares did the CEO sell, and at what prices?

On 12/31/2025, the CEO sold a total of 30,000 shares of Kymera Therapeutics common stock: 23,986 shares at a weighted average price of $77.9508 and 6,014 shares at a weighted average price of $78.5187.

Was the Kymera Therapeutics (KYMR) insider sale under a Rule 10b5-1 trading plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 6, 2024, adopted by the reporting person.

How many Kymera Therapeutics (KYMR) shares does the CEO own after these transactions?

After the reported transactions, the CEO beneficially owned 663,077 shares of Kymera Therapeutics common stock directly.

What is the status of the stock options reported in the Kymera Therapeutics (KYMR) Form 4?

The Form 4 shows a stock option (right to buy) with an exercise price of $2.08 per share covering 30,000 shares of common stock, fully vested and exercisable, and expiring on 11/13/2029. Following the transaction, the reporting person held 275,559 derivative securities (stock options) directly.

What role does the reporting person hold at Kymera Therapeutics (KYMR)?

The reporting person is both a Director and an Officer of Kymera Therapeutics, Inc., serving as the company’s Chief Executive Officer.